세계의 루이소체 치매 치료 시장 : 시장 규모, 점유율, 동향, 업계 분석(약제 유형별, 적응증별, 유통 채널별, 지역별), 예측(2025-2034년)

Lewy Body Dementia Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Type, Indication, Distribution Channel, and Region - Market Forecast, 2025-2034

US $ 4,250 ￦ 5,910,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,250 ￦ 7,301,000

PDF (Multi User License)

PDF 보고서를 동일 기업 20명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,250 ￦ 8,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

Polaris Market Research의 최신 조사에 따르면 세계의 루이소체 치매 치료 시장 규모는 2034년까지 133억 2,000만 달러에 이를 것으로 예측됩니다.

루이소체 치매 치료 시장은 뇌의 비정상적인 단백질 침착에 의해 야기되는 진행성 신경퇴행성 질환인 루이소체 치매(LBD)와 관련된 증상의 관리를 목적으로 한 의학적 치료와 개입에 초점을 맞추었습니다.

이 시장은 세계 인구의 고령화, 신경 퇴행성 질환의 유병률 증가, 진단 툴의 진보에 의한 조기 발견의 향상에 의해 성장을 이루고 있습니다.

루이소체 치매 치료 시장 : 분석 개요

• 2024년 루이소체 치매 치료 시장 점유율은 콜린에스테라아제 억제제가 지배적이었습니다.
• 2024년에는 파킨슨병이 루이소체 치매와 중복하는 병태 때문에 시장을 석권해, 양쪽의 신경 변성 질환에 효과적으로 대처하는 치료에 대한 수요가 높아지고 있습니다.
• 지역별로는 북미가 루이소체 치매 치료 시장에서 최대의 점유율을 차지했으며, 이것은 주로 환자수가 많은 것, 인지도가 높아지고 있는 것, 고도의 의료 인프라가 정비되고 있는 것에 의합니다.
• 루이소체 치매 치료 시장에서는 여러 주요 기업들이 치료 옵션의 진보에 적극적으로 기여하고 있습니다. 이 기업들에는 Eisai Co., Ltd.; Novartis AG; Pfizer Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Johnson & Johnson; Sanofi S.A.; AbbVie Inc.; AstraZeneca plc; Bristol-Myers Squibb Company; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; UCB S.A.; and Otsuka Pharmaceutical Co., Ltd.이 포함됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 분석 방법

제4장 세계의 루이소체 치매 치료 시장 인사이트

• 시장 현황
• 루이소체 치매 치료 시장 역학
  • 성장 촉진요인과 기회
    • 루이소체 치매의 유병률 증가
    • 조사와 임상시험의 진보
  • 억제요인과 과제
    • 효과적인 질환 수식 요법의 부족
• PESTLE 분석
• 루이소체 치매 치료 시장의 활용 동향
• 밸류체인 분석
• COVID-19의 영향 분석

제5장 세계의 루이소체 치매 치료 시장 : 약제 유형별

• 주요 분석 결과
• 소개
• 모다피닐
• 콜린에스테라아제 억제제
• 벤조디아제핀
• 항정신병제
• 항우울제
• 칼비도파 및 레보도파

제6장 세계의 루이소체 치매 치료 시장 : 적응증별

• 주요 분석 결과
• 소개
• 파킨슨병
• 루이소체 치매(DLB)

제7장 세계의 루이소체 치매 치료 시장 : 유통 채널별

• 주요 분석 결과
• 소개
• 약국
• 병원 약국
• 온라인 약국
• 소매 약국

제8장 세계의 루이소체 치매 치료 시장 : 지역별

• 주요 분석 결과
• 소개
  • 루이소체 치매 치료 시장의 분석 : 지역별(2020-2034년)
• 북미
  • 북미 : 약제 유형별(2020-2034년)
  • 북미 : 적응증별(2020-2034년)
  • 북미 : 유통 채널별(2020-2034년)
  • 미국
  • 캐나다
• 유럽
  • 유럽 : 약제 유형별(2020-2034년)
  • 유럽 : 적응증별(2020-2034년)
  • 유럽 : 유통 채널별(2020-2034년)
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 네덜란드
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 아시아태평양: 약제 유형별(2020-2034년)
  • 아시아태평양: 적응증별(2020-2034년)
  • 아시아태평양: 유통 채널별(2020-2034년)
  • 중국
  • 인도
  • 말레이시아
  • 일본
  • 인도네시아
  • 한국
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카
  • 중동 및 아프리카 : 약제 유형별(2020-2034년)
  • 중동 및 아프리카 : 적응증별(2020-2034년)
  • 중동 및 아프리카 : 유통 채널별(2020-2034년)
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 남아프리카
  • 기타 중동 및 아프리카
• 라틴아메리카
  • 라틴아메리카 : 약제 유형별(2020-2034년)
  • 라틴아메리카 : 적응증별(2020-2034년)
  • 라틴아메리카 : 유통 채널별(2020-2034년)
  • 멕시코
  • 브라질
  • 아르헨티나
  • 기타 라틴아메리카

제9장 경쟁 구도

• 사업 확대 및 기업 인수 분석
  • 사업 확대
  • 기업 인수
• 제휴/협업/합의/공개

제10장 기업 프로파일

• AbbVie Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG

JHS

영문 목차

영문목차

The global Lewy body dementia treatment market size is expected to reach USD 13.32 billion by 2034, according to a new study by Polaris Market Research. The report "Lewy Body Dementia Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Type (Modafinil, Cholinesterase Inhibitors, Benzodiazepine, Antipsychotic Drugs, Antidepressants, and Carbidopa-Levodopa), Indication, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Lewy body dementia treatment market focuses on medical therapies and interventions aimed at managing symptoms associated with Lewy body dementia (LBD), a progressive neurodegenerative disorder caused by abnormal protein deposits in the brain. LBD presents with cognitive decline, movement impairments, psychiatric symptoms, and autonomic dysfunction, requiring a combination of pharmacological and non-pharmacological treatments. Medications such as cholinesterase inhibitors, carbidopa-levodopa, and carefully administered antipsychotics are commonly used, while supportive therapies like physical and cognitive rehabilitation play a crucial role in symptom management.

The market is experiencing growth due to an aging global population, increasing prevalence of neurodegenerative diseases, and advancements in diagnostic tools improving early detection. Pharmaceutical companies are investing in research and development, with clinical trials exploring novel drug candidates to enhance treatment efficacy. Additionally, increasing government initiatives and funding for dementia research, coupled with rising healthcare expenditure, create significant Lewy body dementia treatment market opportunities. Trends such as digital health solutions, telemedicine, and personalized medicine are further shaping the market landscape. Furthermore, ongoing innovations and collaborations among key players are expected to drive sustained growth.

Lewy Body Dementia Treatment Market Report Highlights

• Cholinesterase inhibitors dominated the Lewy body dementia treatment market share in 2024. These medications, including donepezil, rivastigmine, and galantamine, function by inhibiting the enzyme cholinesterase, thereby increasing acetylcholine levels in the brain.
• In 2024, the Parkinson's disease segment dominated the market due to its overlapping pathology with Lewy body dementia, driving increased demand for treatments that address both neurodegenerative conditions effectively.
• By region, North America held the largest share in the Lewy body dementia treatment market, primarily due to a significant patient population, increased awareness, and the availability of advanced healthcare infrastructure.
• In the Lewy body dementia treatment market, several key players are actively contributing to advancements in therapeutic options. These companies include Eisai Co., Ltd.; Novartis AG; Pfizer Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Johnson & Johnson; Sanofi S.A.; AbbVie Inc.; AstraZeneca plc; Bristol-Myers Squibb Company; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; UCB S.A.; and Otsuka Pharmaceutical Co., Ltd.

Polaris Market Research has segmented the Lewy body dementia treatment market report on the basis of drug type, indication, distribution channel, and region:

By Drug Type Outlook (Revenue - USD Billion, 2020-2034)

• Modafinil
• Cholinesterase Inhibitors
• Benzodiazepine
• Antipsychotic Drugs
• Antidepressants
• Carbidopa-Levodopa

By Indication Outlook (Revenue - USD Billion, 2020-2034)

• Parkinson's Disease
• Dementia with Lewy Bodies (DLB)

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

• Drug Stores
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa
• Latin America
• Mexico
• Brazil
• Argentina
• Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Source
  • 3.2.1. Primary Source
  • 3.2.2. Secondary Source

4. Global Lewy Body Dementia Treatment Market Insights

• 4.1. Lewy Body Dementia Treatment Market - Market Snapshot
• 4.2. Lewy Body Dementia Treatment Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing prevalence of Lewy body dementia
    • 4.2.1.2. Advancements in research and clinical trials
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Lack of effective disease-modifying therapies
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Lewy Body Dementia Treatment Market Application Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Lewy Body Dementia Treatment Market, by Drug Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
• 5.3. Modafinil
  • 5.3.1. Global Lewy Body Dementia Treatment Market, by Modafinil, by Region, 2020-2034 (USD Billion)
• 5.4. Cholinesterase Inhibitors
  • 5.4.1. Global Lewy Body Dementia Treatment Market, by Cholinesterase Inhibitors, by Region, 2020-2034 (USD Billion)
• 5.5. Benzodiazepine
  • 5.5.1. Global Lewy Body Dementia Treatment Market, by Benzodiazepine, by Region, 2020-2034 (USD Billion)
• 5.6. Antipsychotic Drugs
  • 5.6.1. Global Lewy Body Dementia Treatment Market, by Antipsychotic Drugs, by Region, 2020-2034 (USD Billion)
• 5.7. Antidepressants
  • 5.7.1. Global Lewy Body Dementia Treatment Market, by Antidepressants, by Region, 2020-2034 (USD Billion)
• 5.8. Carbidopa-Levodopa
  • 5.8.1. Global Lewy Body Dementia Treatment Market, by Carbidopa-Levodopa, by Region, 2020-2034 (USD Billion)

6. Global Lewy Body Dementia Treatment Market, by Indication

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
• 6.3. Parkinson's Disease
  • 6.3.1. Global Lewy Body Dementia Treatment Market, by Parkinson's Disease, by Region, 2020-2034 (USD Billion)
• 6.4. Dementia with Lewy Bodies (DLB)
  • 6.4.1. Global Lewy Body Dementia Treatment Market, by Dementia with Lewy Bodies (DLB), by Region, 2020-2034 (USD Billion)

7. Global Lewy Body Dementia Treatment Market, by Distribution Channel

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
• 7.3. Drug Stores
  • 7.3.1. Global Lewy Body Dementia Treatment Market, by Drug Stores, by Region, 2020-2034 (USD Billion)
• 7.4. Hospitals Pharmacies
  • 7.4.1. Global Lewy Body Dementia Treatment Market, by Hospitals Pharmacies, by Region, 2020-2034 (USD Billion)
• 7.5. Online Pharmacies
  • 7.5.1. Global Lewy Body Dementia Treatment Market, by Online Pharmacies, by Region, 2020-2034 (USD Billion)
• 7.6. Retail Pharmacies
  • 7.6.1. Global Lewy Body Dementia Treatment Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Lewy Body Dementia Treatment Market, by Geography

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Lewy Body Dementia Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
• 8.3. Lewy Body Dementia Treatment Market - North America
  • 8.3.1. North America: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
  • 8.3.2. North America: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
  • 8.3.3. North America: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.3.4. Lewy Body Dementia Treatment Market - U.S.
    • 8.3.4.1. U.S.: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.3.4.2. U.S.: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.3.4.3. U.S.: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.3.5. Lewy Body Dementia Treatment Market - Canada
    • 8.3.5.1. Canada: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.3.5.2. Canada: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.3.5.3. Canada: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
• 8.4. Lewy Body Dementia Treatment Market - Europe
  • 8.4.1. Europe: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
  • 8.4.2. Europe: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
  • 8.4.3. Europe: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.4. Lewy Body Dementia Treatment Market - UK
    • 8.4.4.1. UK: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.4.2. UK: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.4.3. UK: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.5. Lewy Body Dementia Treatment Market - France
    • 8.4.5.1. France: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.5.2. France: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.5.3. France: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.6. Lewy Body Dementia Treatment Market - Germany
    • 8.4.6.1. Germany: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.6.2. Germany: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.6.3. Germany: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.7. Lewy Body Dementia Treatment Market - Italy
    • 8.4.7.1. Italy: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.7.2. Italy: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.7.3. Italy: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.8. Lewy Body Dementia Treatment Market - Spain
    • 8.4.8.1. Spain: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.8.2. Spain: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.8.3. Spain: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.9. Lewy Body Dementia Treatment Market - Netherlands
    • 8.4.9.1. Netherlands: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.9.2. Netherlands: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.9.3. Netherlands: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.10. Lewy Body Dementia Treatment Market - Russia
    • 8.4.10.1. Russia: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.10.2. Russia: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.10.3. Russia: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4.11. Lewy Body Dementia Treatment Market - Rest of Europe
    • 8.4.11.1. Rest of Europe: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.4.11.2. Rest of Europe: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.4.11.3. Rest of Europe: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
• 8.5. Lewy Body Dementia Treatment Market - Asia Pacific
  • 8.5.1. Asia Pacific: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
  • 8.5.2. Asia Pacific: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
  • 8.5.3. Asia Pacific: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.4. Lewy Body Dementia Treatment Market - China
    • 8.5.4.1. China: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.4.2. China: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.4.3. China: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.5. Lewy Body Dementia Treatment Market - India
    • 8.5.5.1. India: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.5.2. India: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.5.3. India: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.6. Lewy Body Dementia Treatment Market - Malaysia
    • 8.5.6.1. Malaysia: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.6.2. Malaysia: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.6.3. Malaysia: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.7. Lewy Body Dementia Treatment Market - Japan
    • 8.5.7.1. Japan: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.7.2. Japan: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.7.3. Japan: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.8. Lewy Body Dementia Treatment Market - Indonesia
    • 8.5.8.1. Indonesia: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.8.2. Indonesia: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.8.3. Indonesia: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.9. Lewy Body Dementia Treatment Market - South Korea
    • 8.5.9.1. South Korea: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.9.2. South Korea: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.9.3. South Korea: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.10. Lewy Body Dementia Treatment Market - Australia
    • 8.5.10.1. Australia: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.10.2. Australia: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.10.3. Australia: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5.11. Lewy Body Dementia Treatment Market - Rest of Asia Pacific
    • 8.5.11.1. Rest of Asia Pacific: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.5.11.2. Rest of Asia Pacific: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.5.11.3. Rest of Asia Pacific: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
• 8.6. Lewy Body Dementia Treatment Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
  • 8.6.2. Middle East & Africa: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
  • 8.6.3. Middle East & Africa: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6.4. Lewy Body Dementia Treatment Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.6.4.2. Saudi Arabia: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.6.4.3. Saudi Arabia: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6.5. Lewy Body Dementia Treatment Market - UAE
    • 8.6.5.1. UAE: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.6.5.2. UAE: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.6.5.3. UAE: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6.6. Lewy Body Dementia Treatment Market - Israel
    • 8.6.6.1. Israel: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.6.6.2. Israel: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.6.6.3. Israel: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6.7. Lewy Body Dementia Treatment Market - South Africa
    • 8.6.7.1. South Africa: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.6.7.2. South Africa: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.6.7.3. South Africa: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6.8. Lewy Body Dementia Treatment Market - Rest of Middle East & Africa
    • 8.6.8.1. Rest of Middle East & Africa: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.6.8.2. Rest of Middle East & Africa: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.6.8.3. Rest of Middle East & Africa: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
• 8.7. Lewy Body Dementia Treatment Market - Latin America
  • 8.7.1. Latin America: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
  • 8.7.2. Latin America: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
  • 8.7.3. Latin America: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7.4. Lewy Body Dementia Treatment Market - Mexico
    • 8.7.4.1. Mexico: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.7.4.2. Mexico: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.7.4.3. Mexico: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7.5. Lewy Body Dementia Treatment Market - Brazil
    • 8.7.5.1. Brazil: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.7.5.2. Brazil: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.7.5.3. Brazil: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7.6. Lewy Body Dementia Treatment Market - Argentina
    • 8.7.6.1. Argentina: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.7.6.2. Argentina: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.7.6.3. Argentina: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7.7. Lewy Body Dementia Treatment Market - Rest of Latin America
    • 8.7.7.1. Rest of Latin America: Lewy Body Dementia Treatment Market, by Drug Type, 2020-2034 (USD Billion)
    • 8.7.7.2. Rest of Latin America: Lewy Body Dementia Treatment Market, by Indication, 2020-2034 (USD Billion)
    • 8.7.7.3. Rest of Latin America: Lewy Body Dementia Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. AbbVie Inc.
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. AstraZeneca plc
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Bristol-Myers Squibb Company
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Eisai Co., Ltd.
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Eli Lilly and Company
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. F. Hoffmann-La Roche Ltd
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. GlaxoSmithKline plc
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Johnson & Johnson
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Merck & Co., Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Novartis AG
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development

관련자료